DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,178,317 B2 Roberts Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,178,317 B2 Roberts Et Al US008178317B2 (12) United States Patent (10) Patent No.: US 8,178,317 B2 Roberts et al. (45) Date of Patent: May 15, 2012 (54) COMPOSITIONS AND METHODS FOR Mende, I. et al., “Oncogenic Transformation Induced by Membrane IDENTIFYING TRANSFORMING AND Targeted AKT2 and AKT3.” Oncogene 20:4419-4423 (2001). TUMIOR SUPPRESSOR GENES Invitation to Pay Additional Fees and Partial International Search Report dated Oct. 14, 2008 from PCT/US2008/062230. (75) Inventors: Thomas M. Roberts, Cambridge, MA Bamford et al., “The COSMIC (Catalogue of Somatic Mutations in (US); Jean Zhao, Brookline, MA (US); Cancer) database and website.” British Journal of Cancer, 91:355 David E. Hill, Arlington, MA (US); 358 (2004). Bartkova et al., “Cyclin D1 protein expression and function in human William C. Hahn, Newton, MA (US); breast cancer.” Int. J. Cancer, 57(3):353-361 (1994). Jesse Boehm, Jamaica Plain, MA (US) Berger et al., “Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells.” Cancer Research, 64:8867-8875 (73) Assignee: Dana-Farber Cancer Institute, Inc., (2004). Boston, MA (US) Boehm et al., “Transformation of Human and Murine Fibroblasts without Viral Oncoproteins.” Molecular and Cellular Biology, *) Notice: Subject to anyy disclaimer, the term of this 25(15):6464-6474 (2005). patent is extended or adjusted under 35 Brown et al., "Control of IkappaB-alphaproteolysis by site-specific, U.S.C. 154(b) by 233 days. signal-induced phosphorylation.” Science, 267: 1485-1488 (1995). Brunet et al., “Constitutively active mutants of MAP kinase kinase (21) Appl. No.: 12/150,941 (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts.” Oncogene, 9(11):3379-3387 (1994). (22) Filed: May 1, 2008 Carroll et al., “The TEL/platelet-derived growth factor B receptor (PDGFBR) fusion in chronic myelomonocytic leukemia is a trans (65) Prior Publication Data forming protein that self-associates and activates PDGFBR kinase US 2009/OO47675A1 Feb. 19, 2009 dependent signaling pathways.” Proc. Natl. Acad. Sci. USA, 93: 14845-14850 (1996). Related U.S. Application Data Chudnovsky et al., “Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.” Nat. Genet., 37(7):745 (60) Provisional application No. 60/927,066, filed on May 749 (2005). 1, 2007. Davies et al., “Mutations of the BRAF gene in human cancer.” Nature, 417:949-954 (2002). (51) Int. Cl. Downward, J., “Targeting RAS signalling pathways in cancer CI2P2/06 (2006.01) therapy.” Nat. Rev. Cancer, 3(1):11-22 (2003). C7H 2L/02 (2006.01) Eisenhaber et al., “Post-translational GPI lipid anchor modification of proteins in kingdoms of life: analysis of protein sequence data (52) U.S. Cl. ...................................... 435/69.1:536/23.1 from complete genomes.” Protein Engineering, 14(1):17-25 (2001). (58) Field of Classification Search ................. 536/23.1; Elenbaas et al., “Heterotypic signaling between epithelial tumor cells 435/69.1 and fibroblasts incarcinoma formation.” Exp. Cell Res., 264(1): 169 See application file for complete search history. 184 (2001). Fan et al., “Homo- and Hetero-Oligomerization of the c-Abl Kinase (56) References Cited and Abelson-linteractor-1.” Cancer Research, 63:873-877 (2003). Farrar et al., “Activation of the Raf-1 kinase cascade by U.S. PATENT DOCUMENTS coumermycin-induced dimerization.” Nature, 383:178-181 (1996). Fitzergerald et al., “IKKepsilon and TBK1 are essential components 5,741,899 A * 4/1998 Capon et al. ................. 536,234 of the IRF3 signaling pathway.” Nat. Immunol. 4(5):491-496 (2003). 6,916,846 B2 7/2005 Farrar et al. Garraway et al., “Integrative genomic analyses identify MITF as a 2004/008 1647 A1* 4/2004 Afeyan et al. .............. 424/94.63 lineage Survival oncogene amplified in malignant melanoma.” FOREIGN PATENT DOCUMENTS Nature, 436:117-122 (2005). WO WO-01/83808 11, 2001 (Continued) OTHER PUBLICATIONS Primary Examiner — Karen Carlson Golubet al. 1994: Fusion of PDGF receptor to a novelets-like gene, (74) Attorney, Agent, or Firm — Foley Hoag LLP tel, in chronic myelomonocytic leukemia with t(5; 12) chromosomal translocation. Cell. 77:307-316. (57) ABSTRACT Maeda et al. 2005, published on-line 2004; Transforming property of TEL-FGFR3 mediated through P13-K in a T-cell lymphoma that Provided herein are nucleic acids, proteins, vectors, cells, Subsequently progressed to aML. Blood 105(5):2115-2123.* kits, devices and methods useful for identifying regulatable Jarvik et al. 1998; Epitope tagging. Annual Review of Genetics. proteins that are able to complement components of cellular 32:601-618. signaling pathways. Also provided are compositions and McWhirter et al. 1993: A coiled-coil oligomerization domain of Bcr methods using these complementing genes directly as mark is essential for the transforming function of Bcr-ABL oncoproteins. ers for cancer diagnosis or prognosis and as targets for anti Molecular and cellular Biology. 13(12): 7587-7595.* Aoki, M. et al., “The AKT Kinase: Molecular Determinants of neoplastic therapeutics. Further provided are methods for Oncogenicity.” Proc. Natl. Acad. Sci. USA95:14950-14955 (1998). using changes caused by expression of the complementing Boehm, J.S. et al., “Integrative Genomic Approaches Identify genes to indirectly identify associated genes to be used as IKBKE as a Breast Cancer Oncogene.” Cell 129:1065-1079 (2007). markers for cancer diagnosis or prognosis and as targets for Jaaro, H. et al., “A Genome Wide Screening Approach for Mem anti-neoplastic therapeutics. brane-Targeted Proteins.” Molec. Cell. Proteomics 4:328-333 (2005). 35 Claims, 20 Drawing Sheets US 8,178,317 B2 Page 2 OTHER PUBLICATIONS Peters et al., “IKKepsilon is part of a novel PMA-inducible IkappaB Golubet al., “Oligomerization of the ABLTyrosine Kinase by the Ets kinase complex.” Mol. Cell, 5(3):513-522 (2000). Protein TEL in Human Leukemia.” Molecular and Cellular Biology, Pinkel et al., “High Resolution analysis of DNA copy number varia 16(8):4107-4116 (1996). tion using comparative genomic hybridization to microarrays.” Nat. Hahn et al., “Creation of human tumour cells with defined genetic Genet., 2002): 207-211 (1998). elements.” Nature, 400:464-468 (1999). Pollocket al., “Regulation of gene expression with synthetic dimer Hahn et al., “Enumeration of the Simian Virus 40 Early Region izers.” Methods Enzymol. 306:263-281 (1999). Elements Necessary for Human Cell Transformation.” Molecular and Ramaswamy et al., “Regulation of G progression by the PTEN Cellular Biology, 22(7):2111-2123 (2002). tumor Suppressor protein is linked to inhibition of the Hanks et al., “The protein kinase family: conserved features and phosphatidylinositol 3-kinase / Akt pathway.” Proc. Natl. Acad. Sci. deduced phylogeny of the catalytic domains.” Science, 241:42-52 USA, 96:2110-2115 (1999). (1988). Rennstam et al., “Patterns of Chromosomal Imbalances Defines Sub Harbury et al., “A switch between two-, three-, and four-stranded groups of Breast Cancer with Distinct Clinical Features and Progno coiled coils in GCN4 leucine zipper mutants.” Science, 262: 1401-7 sis. A Study of 305 Tumors by Comparative Genomic Hybridiza (1993). tion.” Cancer Research, 63.8861-8868 (2003). Harris et al., “Nuclear Accumulation of cRel following C-Terminal Rich et al., “A Genetically Tractable Model of Human Glioma For phosphorylation by TBK1/1KKEe 1.” J. Immunol., 177:2527-2535 mation.” Cancer Research, 61:3556-3560 (2001). (2006). Rivera, V.M.. “Controlling Gene Expression Using Synthetic Hunter, T., "Cooperation between oncogenes.” Cell, 64(2):249-270 Ligands.” Methods, 14(4):421-429 (1998). (1991). Romashkova et al., “NF-kappaB is a target of AKT in anti-apoptotic Johnson et al., “Genetic and biochemical studies of protein PDGF signaling.” Nature, 401:86-90 (1999). N-myristoylation.” Annu. Rev. Biochem, 63:869-914 (1994). Rual et al., "Human ORFeome Version 1.1: A Platform for Reverse Kendall et al., “A Network of Genetic Events Sufficient to Convert Proteomics.” Genome Research, 14:2128-2135 (2004). Normal Human Cells to a Tumorigenic State.” Cancer Res.65:9824 Serrano et al., “Oncogenic ras provokes premature cell senescence 9828 (2005). associated with accumulation of p53 and p16INK4a. Cell, Klippel et al., “Membrane Localization of Phosphatidylinosital 88(5):593-602 (1997). 3-Kinase Is Sufficient to Activate Multiple Signal-Transducing Sharma et al., “Triggering the interferomantiviral response through Kinase Pathways.” Molecular and Cellular Biology, 16(8):4117 an IKK-related pathway.” Science, 300: 1148-1151 (2003). 4127 (1996). Sigal et al., “Amino-terminal basic residues of Src mediate mem Kohn et al., “Akt, a Pleckstrin Homology Domain Containing brane binding through electrostatic interaction with acidic Kinase, Is Activated Primarily by Phosphorylation.” J. Biol. Chem. phospholipids.” Proc. Natl. Acad. Sci. USA,91: 12253-12257 (1994). 271 (36): 21920-21926 (1996). Stanton et al., “Definition of the Human raf Amino-Terminal Regu Li et al., “A novel conditional Akt survival Switch reversibly pro latory Region by Deletion Mutagenesis.” Molecular and Cellular tects cells from apoptosis.” Gene Therapy, 9:233-244 (2002). Biology, 9(2):639-647 (1989). Lundberg et al., “Immortalization and transformation of primary Towler et al., “The biology and enzymology of eukaryotic protein human airway epithelial cells by genetransfer.” Oncogene, 21:4577 acylation.” Annu. Rev. Biochem, 57:69-99 (1988). 4586 (2002). Ung et al., “Heterologous dimerization domains functionally Substi
Load more

Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • ALS2CR2 (STRADB) 406-418) Goat Polyclonal Antibody – AP08962PU-N
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for AP08962PU-N ALS2CR2 (STRADB) 406-418) Goat Polyclonal Antibody Product data: Product Type: Primary Antibodies Applications: ELISA, IHC, WB Recommended Dilution: ELISA: 1/32000. Immunohistochemistry on Paraffin Sections: 3.75 µg/ml. Western Blot: 1 - 3 µg/ml. Reactivity: Canine, Human Host: Goat Clonality: Polyclonal Immunogen: Synthetic peptide from C-terminus of human ALS2CR2 Specificity: This antibody reacts to STE20-Related Kinase Adaptor Beta (STRADB/ALS2CR2) at aa 406-418. It is expected to recognise both human isoforms: ILPIP-alpha (NP_061041.2) and ILPIP-beta (AAF71042.1). Formulation: Tris saline buffer, pH 7.3, 0.5% BSA, 0.02% sodium azide State: Aff - Purified State: Liquid purified Ig Concentration: lot specific Purification: Immunoaffinity Chromatography Conjugation: Unconjugated Storage: Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Stability: Shelf life: one year from despatch. Database Link: Entrez Gene 55437 Human Q9C0K7 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 ALS2CR2 (STRADB) 406-418) Goat Polyclonal Antibody – AP08962PU-N Background: Amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2, is connected to transferase/kinase activity and ATP binding, it has recently been shown to interact with XIAP, a member of the IAP (Inhibitor of Apoptosis) protein family.
    [Show full text]
  • Analysis of the Human Serum Proteome
    Cedarville University DigitalCommons@Cedarville Pharmaceutical Sciences Faculty Publications Department of Pharmaceutical Sciences 6-2004 Analysis of the Human Serum Proteome King C. Chan David A. Lucas Denise Hise Carl F. Schaefer Zhen Xiao See next page for additional authors Follow this and additional works at: https://digitalcommons.cedarville.edu/ pharmaceutical_sciences_publications Part of the Pharmacy and Pharmaceutical Sciences Commons This Article is brought to you for free and open access by DigitalCommons@Cedarville, a service of the Centennial Library. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Publications by an authorized administrator of DigitalCommons@Cedarville. For more information, please contact [email protected]. Authors King C. Chan, David A. Lucas, Denise Hise, Carl F. Schaefer, Zhen Xiao, George M. Janini, Kenneth H. Buetow, Haleem J. Issaq, Timothy D. Veenstra, and Thomas P. Conrads Clinical Proteomics Journal Copyright ©Humana Press Inc. All rights of any nature whatsoever are reserved. ISSN 1542-6416/04/01:101–225/$25.00 Serum/Plasma Proteome Analysis of the Human Serum Proteome King C. Chan,1,† David A. Lucas,1,† Denise Hise,2 Carl F. Schaefer,2 Zhen Xiao,1 George M. Janini,1 Kenneth H. Buetow,2 Haleem J. Issaq,1 Timothy D.Veenstra,1 and Thomas P. Conrads1,* 1Laboratory of Proteomics and Analytical Technologies, National Cancer Institute at Frederick, SAIC-Frederick, Inc, PO Box B, Frederick, MD 21702 2Center for Bioinformatics, National Cancer Institute, Bethesda, MD 20892 †These authors contributed equally to this work. each of which was analyzed by microcapillary Abstract reversed-phase liquid chromatography coupled Changes in serum proteins that signal online with MS/MS analysis.
    [Show full text]
  • Profiling Data
    Compound Name DiscoveRx Gene Symbol Entrez Gene Percent Compound Symbol Control Concentration (nM) JNK-IN-8 AAK1 AAK1 69 1000 JNK-IN-8 ABL1(E255K)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317I)-nonphosphorylated ABL1 87 1000 JNK-IN-8 ABL1(F317I)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317L)-nonphosphorylated ABL1 65 1000 JNK-IN-8 ABL1(F317L)-phosphorylated ABL1 61 1000 JNK-IN-8 ABL1(H396P)-nonphosphorylated ABL1 42 1000 JNK-IN-8 ABL1(H396P)-phosphorylated ABL1 60 1000 JNK-IN-8 ABL1(M351T)-phosphorylated ABL1 81 1000 JNK-IN-8 ABL1(Q252H)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(Q252H)-phosphorylated ABL1 56 1000 JNK-IN-8 ABL1(T315I)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(T315I)-phosphorylated ABL1 92 1000 JNK-IN-8 ABL1(Y253F)-phosphorylated ABL1 71 1000 JNK-IN-8 ABL1-nonphosphorylated ABL1 97 1000 JNK-IN-8 ABL1-phosphorylated ABL1 100 1000 JNK-IN-8 ABL2 ABL2 97 1000 JNK-IN-8 ACVR1 ACVR1 100 1000 JNK-IN-8 ACVR1B ACVR1B 88 1000 JNK-IN-8 ACVR2A ACVR2A 100 1000 JNK-IN-8 ACVR2B ACVR2B 100 1000 JNK-IN-8 ACVRL1 ACVRL1 96 1000 JNK-IN-8 ADCK3 CABC1 100 1000 JNK-IN-8 ADCK4 ADCK4 93 1000 JNK-IN-8 AKT1 AKT1 100 1000 JNK-IN-8 AKT2 AKT2 100 1000 JNK-IN-8 AKT3 AKT3 100 1000 JNK-IN-8 ALK ALK 85 1000 JNK-IN-8 AMPK-alpha1 PRKAA1 100 1000 JNK-IN-8 AMPK-alpha2 PRKAA2 84 1000 JNK-IN-8 ANKK1 ANKK1 75 1000 JNK-IN-8 ARK5 NUAK1 100 1000 JNK-IN-8 ASK1 MAP3K5 100 1000 JNK-IN-8 ASK2 MAP3K6 93 1000 JNK-IN-8 AURKA AURKA 100 1000 JNK-IN-8 AURKA AURKA 84 1000 JNK-IN-8 AURKB AURKB 83 1000 JNK-IN-8 AURKB AURKB 96 1000 JNK-IN-8 AURKC AURKC 95 1000 JNK-IN-8
    [Show full text]
  • PHKG2, Active (SRP5062)
    PHKG2, active, GST tagged, human PRECISIOÒ Kinase recombinant, expressed in Sf9 cells Catalog Number SRP5062 Storage Temperature –70°C Synonyms: GSD9C Figure 1. SDS-PAGE Gel of Typical Lot Product Description 70–95% (densitometry) PHKG2 is the hepatic and testis isoform of the gamma subunit of phosphorylase kinase. PHKG2 gene contains 10 exons and spans 9.5 kb and maps to chromosome 16p12.1-p11.2.1 Deficiency of PHK, a regulatory enzyme of glycogen metabolism, is responsible for 25% of all cases of glycogen storage disease and is genetically and clinically heterogeneous. Mutations in the PHKG2 gene lead to autosomal liver-specific PHK deficiency (glycogen storage disease IXc) and an increased risk of cirrhosis, and at least 11 PHKG2 mutations have been identified to date.2 Figure 2. Specific Activity of Typical Lot Recombinant, full-length, human PHKG2 was 59–81 nmole/min/mg expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. The gene accession number is NM_000294. Recombinant protein stored in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.25 mM DTT, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol. Molecular mass: ~70 kDa Purity: 70–95% (SDS-PAGE, see Figure 1) Specific Activity: 59–81 nmole/min/mg (see Figure 2) Precautions and Disclaimer Procedure This product is for R&D use only, not for drug, Preparation Instructions household, or other uses. Please consult the Material Kinase Assay Buffer – 25 mM MOPS, pH 7.2, 12.5 mM Safety Data Sheet for information regarding hazards glycerol 2-phosphate, 25 mM MgCl2, 5 mM EGTA, and and safe handling practices.
    [Show full text]
  • Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids
    Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene,
    [Show full text]
  • Prognostic and Immune Implications of a Novel Ferroptosis-Related Ten-Gene Signature in Lung Adenocarcinoma
    1058 Original Article Page 1 of 26 Prognostic and immune implications of a novel ferroptosis-related ten-gene signature in lung adenocarcinoma Chao Ma1,2^, Feng Li1,3, Huan Luo1 1Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany; 2Berlin Institute of Health Center for Regenerative Therapies and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité – Universitätsmedizin Berlin, Berlin, Germany; 3Department of Surgery, Competence Center of Thoracic Surgery, Charité University Hospital Berlin, Berlin, Germany Contributions: (I) Conception and design: C Ma; (II) Administrative support: C Ma; (III) Provision of study materials or patients: C Ma, F Li; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: C Ma; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Chao Ma. Berlin Institute of Health Center for Regenerative Therapies and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité – Universitätsmedizin Berlin, Berlin, Germany. Email: [email protected]. Background: Lung cancer has been the focus of attention for many researchers in recent years due to its leading contribution to cancer-related death worldwide, with lung adenocarcinoma (LUAD) being the most common histological type. Ferroptosis, a novel iron-dependent form of regulated cell death, can be induced by sorafenib. Emerging evidence shows that triggering ferroptosis has potential as a cancer therapy. This work aimed to build a ferroptosis-related gene signature for predicting the outcome of LUAD. Methods: The TCGA-LUAD dataset was set as the training cohort, and the GSE72094 and GSE68465 datasets were set as the validation cohorts.
    [Show full text]
  • Full Disclosure Forms
    Expanding genotype/phenotype of neuromuscular diseases by comprehensive target capture/NGS Xia Tian, PhD* ABSTRACT * Wen-Chen Liang, MD Objective: To establish and evaluate the effectiveness of a comprehensive next-generation * Yanming Feng, PhD sequencing (NGS) approach to simultaneously analyze all genes known to be responsible for Jing Wang, MD the most clinically and genetically heterogeneous neuromuscular diseases (NMDs) involving spi- Victor Wei Zhang, PhD nal motoneurons, neuromuscular junctions, nerves, and muscles. Chih-Hung Chou, MS Methods: All coding exons and at least 20 bp of flanking intronic sequences of 236 genes causing Hsien-Da Huang, PhD NMDs were enriched by using SeqCap EZ solution-based capture and enrichment method fol- Ching Wan Lam, PhD lowed by massively parallel sequencing on Illumina HiSeq2000. Ya-Yun Hsu, PhD ; 3 Thy-Sheng Lin, MD Results: The target gene capture/deep sequencing provides an average coverage of 1,000 per Wan-Tzu Chen, MS nucleotide. Thirty-five unrelated NMD families (38 patients) with clinical and/or muscle pathologic Lee-Jun Wong, PhD diagnoses but without identified causative genetic defects were analyzed. Deleterious mutations Yuh-Jyh Jong, MD were found in 29 families (83%). Definitive causative mutations were identified in 21 families (60%) and likely diagnoses were established in 8 families (23%). Six families were left without diagnosis due to uncertainty in phenotype/genotype correlation and/or unidentified causative Correspondence to genes. Using this comprehensive panel, we not only identified mutations in expected genes but Dr. Wong: also expanded phenotype/genotype among different subcategories of NMDs. [email protected] or Dr. Jong: Conclusions: Target gene capture/deep sequencing approach can greatly improve the genetic [email protected] diagnosis of NMDs.
    [Show full text]
  • The Dual Role of Micrornas in Colorectal Cancer Progression
    International Journal of Molecular Sciences Review The Dual Role of MicroRNAs in Colorectal Cancer Progression Lei Ding 1,2,†, Zhenwei Lan 1,2,†, Xianhui Xiong 1,2, Hongshun Ao 1,2, Yingting Feng 1,2, Huan Gu 1,2, Min Yu 1,2 and Qinghua Cui 1,2,* 1 Lab of Biochemistry & Molecular Biology, School of Life Sciences, Yunnan University, Kunming 650091, China; [email protected] (L.D.); [email protected] (Z.L.); [email protected] (X.X.); [email protected] (H.A.); [email protected] (Y.F.); [email protected] (H.G.); [email protected] (M.Y.) 2 Key Lab of Molecular Cancer Biology, Yunnan Education Department, Kunming 650091, China * Correspondence: [email protected]; Tel.: +86-871-65031412 † These authors contributed equally to this work. Received: 29 August 2018; Accepted: 13 September 2018; Published: 17 September 2018 Abstract: Colorectal cancer (CRC) is responsible for one of the major cancer incidence and mortality worldwide. It is well known that MicroRNAs (miRNAs) play vital roles in maintaining the cell development and other physiological processes, as well as, the aberrant expression of numerous miRNAs involved in CRC progression. MiRNAs are a class of small, endogenous, non-coding, single-stranded RNAs that bind to the 3’-untranslated region (30-UTR) complementary sequences of their target mRNA, resulting in mRNA degradation or inhibition of its translation as a post-transcriptional regulators. Moreover, miRNAs also can target the long non-coding RNA (lncRNA) to regulate the expression of its target genes involved in proliferation and metastasis of CRC. The functions of these dysregulated miRNAs appear to be context specific, with evidence of having a dual role in both oncogenes and tumor suppression depending on the cellular environment in which they are expressed.
    [Show full text]
  • Newly Identified Gon4l/Udu-Interacting Proteins
    www.nature.com/scientificreports OPEN Newly identifed Gon4l/ Udu‑interacting proteins implicate novel functions Su‑Mei Tsai1, Kuo‑Chang Chu1 & Yun‑Jin Jiang1,2,3,4,5* Mutations of the Gon4l/udu gene in diferent organisms give rise to diverse phenotypes. Although the efects of Gon4l/Udu in transcriptional regulation have been demonstrated, they cannot solely explain the observed characteristics among species. To further understand the function of Gon4l/Udu, we used yeast two‑hybrid (Y2H) screening to identify interacting proteins in zebrafsh and mouse systems, confrmed the interactions by co‑immunoprecipitation assay, and found four novel Gon4l‑interacting proteins: BRCA1 associated protein‑1 (Bap1), DNA methyltransferase 1 (Dnmt1), Tho complex 1 (Thoc1, also known as Tho1 or HPR1), and Cryptochrome circadian regulator 3a (Cry3a). Furthermore, all known Gon4l/Udu‑interacting proteins—as found in this study, in previous reports, and in online resources—were investigated by Phenotype Enrichment Analysis. The most enriched phenotypes identifed include increased embryonic tissue cell apoptosis, embryonic lethality, increased T cell derived lymphoma incidence, decreased cell proliferation, chromosome instability, and abnormal dopamine level, characteristics that largely resemble those observed in reported Gon4l/udu mutant animals. Similar to the expression pattern of udu, those of bap1, dnmt1, thoc1, and cry3a are also found in the brain region and other tissues. Thus, these fndings indicate novel mechanisms of Gon4l/ Udu in regulating CpG methylation, histone expression/modifcation, DNA repair/genomic stability, and RNA binding/processing/export. Gon4l is a nuclear protein conserved among species. Animal models from invertebrates to vertebrates have shown that the protein Gon4-like (Gon4l) is essential for regulating cell proliferation and diferentiation.
    [Show full text]
  • Thesis Reference
    Thesis A kinome-wide RNAi screen to identify genes controlling membrane lipid homeostasis in human cells GEHIN, Charlotte Abstract The control of lipid homeostasis is a fundamental process that allows cells to maintain the unique lipid composition of their membrane compartments and to deal with the energetic fluxes from metabolism. If most of enzymes involved in lipid metabolism are characterized, the question of the genetic control of lipid homeostasis is still outstanding. In order to find genes that control the homeostasis of membrane lipids, I combined a large-scale RNAi screen targeting the human knome with the techniques of targeted lipidomic analysis by mass spectrometry to monitor lipid changes in HeLa cells. Data analysis of the screen allowed the characterization of candidate genes involved in the control of membrane lipid homeostasis. In parallel, in the context of the NCCR Chemical Biology, I developed a robotically-assisted siRNA transfection assay and screened a library of chemicals potentially able to transfect siRNA in Human cells at least as efficiently than commercially available compounds. Reference GEHIN, Charlotte. A kinome-wide RNAi screen to identify genes controlling membrane lipid homeostasis in human cells. Thèse de doctorat : Univ. Genève, 2014, no. Sc. 4670 URN : urn:nbn:ch:unige-380353 DOI : 10.13097/archive-ouverte/unige:38035 Available at: http://archive-ouverte.unige.ch/unige:38035 Disclaimer: layout of this document may differ from the published version. 1 / 1 UNIVERSITÉ DE GENÈVE FACULTÉ DES SCIENCES
    [Show full text]
  • Cyclin F-Chk1 Synthetic Lethality Mediated by E2F1 Degradation
    bioRxiv preprint doi: https://doi.org/10.1101/509810; this version posted January 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Cyclin F-Chk1 synthetic lethality mediated by E2F1 degradation Kamila Burdova1, Hongbin Yang1, Roberta Faedda1, Samuel Hume1, Daniel Ebner2, Benedikt M Kessler2, Iolanda Vendrell1,2, David H Drewry3, Carrow I Wells3, Stephanie B Hatch2, Vincenzo D’Angiolella1* 1Medical Research Council Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK 2Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7FZ, UK 3Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America * Corresponding Author: [email protected] Summary Cyclins are central engines of cell cycle progression when partnered with Cyclin Dependent Kinases (CDKs). Among the different cyclins controlling cell cycle progression, cyclin F does not partner with a CDK, but forms an E3 ubiquitin ligase, assembling through the F-box domain, an Skp1-Cul1-F-box (SCF) module. Although multiple substrates of cyclin F have been identified the vulnerabilities of cells lacking cyclin F are not known. Thus, we assessed viability of cells lacking cyclin F upon challenging cells with more than 200 kinase inhibitors. The screen revealed a striking synthetic lethality between Chk1 inhibition and cyclin F loss.
    [Show full text]